John Librie

John Librie has extensive experience in the biopharmaceutical industry, currently serving as the Chief Executive Officer at Vida Pharmacal since 2021 and as President & CEO at Velcision, LLC since 2009. Previously, John held various executive roles, including Chief Executive Officer at Cellular Preservation Technologies from 2017 to 2021 and President & Chief Executive Officer at ONY, Inc. from 2013 to 2017. Additional experience includes serving as Chief Executive Officer/General Manager at Shore Therapeutics, Senior Vice President at Acorda Therapeutics, Vice President at Biotechnology General Corp., and Regional Director at Genentech. John holds an educational background from Fairleigh Dickinson University.